254 related articles for article (PubMed ID: 34277021)
1. Tumor-Treating Fields for the treatment of glioblastoma: a systematic review and meta-analysis.
Regev O; Merkin V; Blumenthal DT; Melamed I; Kaisman-Elbaz T
Neurooncol Pract; 2021 Aug; 8(4):426-440. PubMed ID: 34277021
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of tumor-treating fields therapy for glioblastoma: A single-center study in a Chinese cohort.
She L; Gong X; Su L; Liu C
Front Neurol; 2022; 13():1042888. PubMed ID: 36698900
[TBL] [Abstract][Full Text] [Related]
3. Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice.
Shi W; Blumenthal DT; Oberheim Bush NA; Kebir S; Lukas RV; Muragaki Y; Zhu JJ; Glas M
J Neurooncol; 2020 Jul; 148(3):489-500. PubMed ID: 32535723
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial.
Ram Z; Kim CY; Hottinger AF; Idbaih A; Nicholas G; Zhu JJ
Front Oncol; 2021; 11():671972. PubMed ID: 34692470
[TBL] [Abstract][Full Text] [Related]
5. Concurrent Tumor Treating Fields (TTFields) and Radiation Therapy for Newly Diagnosed Glioblastoma: A Prospective Safety and Feasibility Study.
Bokstein F; Blumenthal D; Limon D; Harosh CB; Ram Z; Grossman R
Front Oncol; 2020; 10():411. PubMed ID: 32373508
[No Abstract] [Full Text] [Related]
6. Tumor treating fields: narrative review of a promising treatment modality for cancer.
Kutuk T; Atak E; La Rosa A; Kotecha R; Mehta MP; Chuong MD
Chin Clin Oncol; 2023 Dec; 12(6):64. PubMed ID: 37953242
[TBL] [Abstract][Full Text] [Related]
7. Tumor Treating Fields (TTFields) therapy vs physicians' choice standard-of-care treatment in patients with recurrent glioblastoma: a post-approval registry study (EF-19).
Zhu JJ; Goldlust SA; Kleinberg LR; Honnorat J; Oberheim Bush NA; Ram Z
Discov Oncol; 2022 Oct; 13(1):105. PubMed ID: 36239858
[TBL] [Abstract][Full Text] [Related]
8. Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis.
Ballo MT; Conlon P; Lavy-Shahaf G; Kinzel A; Vymazal J; Rulseh AM
J Neurooncol; 2023 Aug; 164(1):1-9. PubMed ID: 37493865
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of therapeutics for elderly glioblastoma patients: A Bayesian network analysis.
Zhao B; Wu J; Xia Y; Li H; Wang Y; Qu T; Xing H; Wang Y; Ma W
Pharmacol Res; 2022 Aug; 182():106316. PubMed ID: 35724820
[TBL] [Abstract][Full Text] [Related]
10. Theory and application of TTFields in newly diagnosed glioblastoma.
Yu A; Zeng J; Yu J; Cao S; Li A
CNS Neurosci Ther; 2024 Mar; 30(3):e14563. PubMed ID: 38481068
[TBL] [Abstract][Full Text] [Related]
11. Tumor-treating fields as a fourth treating modality for glioblastoma: a meta-analysis.
Magouliotis DE; Asprodini EK; Svokos KA; Tasiopoulou VS; Svokos AA; Toms SA
Acta Neurochir (Wien); 2018 Jun; 160(6):1167-1174. PubMed ID: 29696502
[TBL] [Abstract][Full Text] [Related]
12. Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study.
Lu G; Rao M; Zhu P; Liang B; El-Nazer RT; Fonkem E; Bhattacharjee MB; Zhu JJ
Front Neurol; 2019; 10():42. PubMed ID: 30766509
[TBL] [Abstract][Full Text] [Related]
13. Tumor treating fields for the treatment of glioblastoma: Current understanding and future perspectives.
Colamaria A; Leone A; Fochi NP; Di Napoli V; Giordano G; Landriscina M; Patel K; Carbone F
Surg Neurol Int; 2023; 14():394. PubMed ID: 38053701
[TBL] [Abstract][Full Text] [Related]
14. Tumor treating fields in glioblastoma: long-term treatment and high compliance as favorable prognostic factors.
Wang J; Du Q; Chen J; Liu J; Gu Z; Wang X; Zhang A; Gao S; Shao A; Zhang J; Wang Y
Front Oncol; 2024; 14():1345190. PubMed ID: 38571508
[TBL] [Abstract][Full Text] [Related]
15. PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma.
Dono A; Mitra S; Shah M; Takayasu T; Zhu JJ; Tandon N; Patel CB; Esquenazi Y; Ballester LY
J Neurooncol; 2021 May; 153(1):153-160. PubMed ID: 33881725
[TBL] [Abstract][Full Text] [Related]
16. Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial.
Kim CY; Paek SH; Nam DH; Chang JH; Hong YK; Kim JH; Kim OL; Kim SH
J Neurooncol; 2020 Feb; 146(3):399-406. PubMed ID: 32020470
[TBL] [Abstract][Full Text] [Related]
17. The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.
Burri SH; Gondi V; Brown PD; Mehta MP
Am J Clin Oncol; 2018 Feb; 41(2):191-196. PubMed ID: 28832384
[TBL] [Abstract][Full Text] [Related]
18. Tumor Treating Fields in the Management of Patients with Malignant Gliomas.
Ghiaseddin AP; Shin D; Melnick K; Tran DD
Curr Treat Options Oncol; 2020 Jul; 21(9):76. PubMed ID: 32734509
[TBL] [Abstract][Full Text] [Related]
19. Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma.
Lazaridis L; Schäfer N; Teuber-Hanselmann S; Blau T; Schmidt T; Oster C; Weller J; Tzaridis T; Pierscianek D; Keyvani K; Kleinschnitz C; Stuschke M; Scheffler B; Deuschl C; Sure U; Herrlinger U; Kebir S; Glas M
J Cancer Res Clin Oncol; 2020 Mar; 146(3):787-792. PubMed ID: 31828428
[TBL] [Abstract][Full Text] [Related]
20. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Toms SA; Kim CY; Nicholas G; Ram Z
J Neurooncol; 2019 Jan; 141(2):467-473. PubMed ID: 30506499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
